Asan Medical Center (Asan Cancer Institute)

Asan Medical Center (AMC) is the largest healthcare facility in South Korea, located in Songpa-gu, Seoul. Founded in 1989 by Chung Ju-yung (founder of the Hyundai Group) under the ASAN Foundation and affiliated with the University of Ulsan College of Medicine, it is a global leader in highly complex tertiary and quaternary care.

The Asan Cancer Institute (ACI) runs a standalone comprehensive cancer hospital, with organ-specific cancer centres, a high-volume robotic surgery unit, a CAR-T cell therapy centre, advanced LINAC and radiosurgery platforms, and precision genomic analysis.

It is consistently ranked among the top hospitals worldwide (Newsweek places AMC among the best in the world overall, and consistently in the global top 5 for cancer care, endocrinology, and gastroenterology).

It has an International Healthcare Center (IHC) providing end-to-end care coordination for thousands of overseas patients each year, including multilingual medical interpretation, visa extensions, airport transfers, and second opinion services.

High-volume surgical success: Leads South Korea in case volume and survival rates for major cancer procedures, including surgery for stomach, liver, pancreatic, biliary, colorectal, and breast cancer.

Precision medicine and genetics: Applies advanced genetic analysis — such as the OncoPanel next-generation sequencing (NGS) test, which examines more than 300 cancer genes for each patient — to personalise targeted therapy.

Targeted therapy and immunotherapy: Delivers advanced systemic drug treatments at high volume, supporting more than 200,000 chemotherapy infusion visits per year.

It has a dedicated Theranostics Center combining molecular diagnostics (such as PSMA or DOTATOC PET/CT) with targeted radiopharmaceutical therapy (such as Lu-177 PSMA or Lu-177 DOTATATE) for prostate cancer and neuroendocrine tumours.

A strong track record and high success rate in bone marrow and haematopoietic stem cell transplantation, including procedures from alternative donors.